Citation Impact
Citing Papers
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
2005 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
2013 StandoutScienceNobel
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
2010 StandoutScience
Guidelines for the welfare and use of animals in cancer research
2010 Standout
Co-incidence of RCC-susceptibility polymorphisms with HIF cis-acting sequences supports a pathway tuning model of cancer
2019 StandoutNobel
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
2012 Standout
High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia
2005
Stromal fibroblasts in cancer initiation and progression
2004 StandoutNature
The role of FLT3 in haematopoietic malignancies
2003
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
2009 Standout
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines
2006 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Lipid nanoparticles for mRNA delivery
2021 Standout
RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome
2007
Gestational trophoblastic disease
2010 Standout
VHL and p53: Tumor Suppressors Team Up to Prevent Cancer
2006 StandoutNobel
HIF-1α Induces Genetic Instability by Transcriptionally Downregulating MutSα Expression
2005 StandoutNobel
Clinical Implications of Novel Mutations in Epigenetic Modifiers in AML
2011
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations
2008 StandoutNobel
Cancer genes and the pathways they control
2004 Standout
Evolution of a designed protein assembly encapsulating its own RNA genome
2017 StandoutNatureNobel
Inflammation and Colon Cancer
2010 Standout
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
2015 Standout
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
2005 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
2009
Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement
2005
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Baffled by Bafilomycin: An Anticancer Agent That Induces Hypoxia-Inducible Factor-1α Expression
2006 StandoutNobel
The Emerging Hallmarks of Cancer Metabolism
2016 Standout
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
The cancer stem cell: premises, promises and challenges
2011 Standout
Eicosanoids and cancer
2010 Standout
Point mutations of protein kinases and individualised cancer therapy
2006
Pancreatic Cancer
2010 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
The chronic myeloproliferative disorders: Clonality and clinical heterogeneity
2004
Organ‐specific profiles of genetic changes in cancers caused by activation‐induced cytidine deaminase expression
2008 StandoutNobel
Development of novel therapeutic strategies that target HIF-1
2006 StandoutNobel
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
2009 StandoutNobel
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
2005 StandoutNature
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
2005 Standout
Mechanisms of Cell Protection by Heme Oxygenase-1
2010 Standout
Acute Myeloid Leukemia
2015 Standout
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
2004
Lignocellulosic biomass: a sustainable platform for the production of bio-based chemicals and polymers
2015 Standout
Nanoparticles in Photodynamic Therapy
2015 Standout
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia
2013
MicroRNAs in Cancer
2009 Standout
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
2007
Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin
2008
Nanoparticle PEGylation for Imaging and Therapy
2011 Standout
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform
2011 Standout
Spontaneous Transformation of Cultured Mouse Bone Marrow–Derived Stromal Cells
2006 StandoutNobel
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
2005
Development of Minimal Residual Disease–Directed Therapy in Acute Myeloid Leukemia
2008
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia
2007
Gold Nanoparticles: A Revival in Precious Metal Administration to Patients
2011 Standout
Intravascular Hemolysis in Aortic Stenosis
2004
Robust Distal Tip Cell Pathfinding in the Face of Temperature Stress Is Ensured by Two Conserved microRNAS inCaenorhabditis elegans
2015 StandoutNobel
Works of Po‐Nan Wang being referenced
Combination of High-Dose Chemotherapy, Autologous Bone Marrow/Peripheral Blood Stem Cell Transplantation, and Thoracoscopic Surgery in Refractory Nongestational Choriocarcinoma of a 45XO/46XY Female: A Case Report
1997
Bone marrow failure and myelofibrosis in a case of PVP storage disease
1998
Internal tandem duplication of fms‐like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome
2004
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
2002
Hemolytic Anemia in Native Valve Infective Endocarditis
1999
Heterogeneous Patterns of FLT3 Asp835 Mutations in Relapsed de Novo Acute Myeloid Leukemia
2004
Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia
2002